ASHNEWS2023

Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Advertisement
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Patrick DalyMyeloma | December 20, 2023
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Advertisement
Patrick DalyMyeloma | December 20, 2023
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Patrick DalyMyeloma | December 20, 2023
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
Leah SherwoodMeeting News | December 18, 2023
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Leah SherwoodMeeting News | December 18, 2023
Researchers said there was a need for potentially more effective one-time-only treatment options.
Melissa BadamoMantle Cell Lymphoma | December 18, 2023
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Hans Lee, MDMyeloma | December 19, 2023
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
Jennifer R. Brown, MD, PhDChronic Lymphocytic Leukemia | December 16, 2023
Dr. Brown presented updated results from the ALPINE study at ASH 2023.
Patrick DalyChronic Lymphocytic Leukemia | December 16, 2023
ELEVATE-TN enrolled 535 patients, of which 179 received acalabrutinib.
Patrick DalyAggressive B-Cell Lymphoma | December 16, 2023
The study included 16 baseline and 18 post-infusion tumor samples from 26 patients.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo.
Carlyn Tan, MDMyeloma | December 15, 2023
The study compared characteristics, step up dosing process, and incidence and management of cytokine release syndrome.
Jennifer Woyach, MDChronic Lymphocytic Leukemia | December 17, 2023
Dr. Woyach joined Chadi Nabhan, MD, MBA, FACP, to discuss the novel BTK inhibitors pirtobrutinib and LP168.
Patrick DalyIndolent B-Cell Lymphoma | February 16, 2024
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Advertisement
Advertisement
Editorial Board